Navigation Links
$2.5 million Defense Department grant funds gene therapy study for Lou Gehrig's disease
Date:4/1/2014

LOS ANGELES (April 1, 2014) The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.

The incurable disorder attacks muscle-controlling nerve cells motor neurons in the brain, brainstem and spinal cord. As the neurons die, the ability to initiate and control muscle movement is lost. Patients experience muscle weakness that steadily leads to paralysis; the disease usually is fatal within five years of diagnosis. Several genes have been identified in familial forms of ALS, but most cases are caused by a complex combination of unknown genetic and environmental factors, experts believe.

Because ALS affects a higher-than-expected percentage of military veterans, especially those returning from overseas duties, the Defense Department invests $7.5 million annually to search for causes and treatments. The Cedars-Sinai study, led by Clive Svendsen, PhD, professor and director of the Regenerative Medicine Institute at Cedars-Sinai Medical Center, and Genevive Gowing, PhD, a senior scientist in his laboratory, also will involve a research team at the University of Wisconsin, Madison and a Netherlands-based biotechnology company, uniQure, that has extensive experience in human gene therapy research and development.

The research will be conducted in laboratory rats bred to model a genetic form of ALS. If successful, it could have implications for patients with other types of the disease and could translate into a gene therapy clinical trial for this devastating disease.

It centers on a protein, GDNF, that promotes the survival of neurons. In theory, transporting GDNF into the spinal cord could protect neurons and slow disease progression, but attempts so far have failed, largely because the protein does not readily penetrate into the spinal cord. Regenerative Medicine Institute scientists previously showed that spinal transplantation of stem cells that were engineered to produce GDNF increased motor neuron survival, but this had no functional benefit because it did not prevent nerve cell deterioration at a critical site, the "neuromuscular junction" the point where nerve fibers connect with muscle fibers to stimulate muscle action.

Masatoshi Suzuki, PhD, DVM, assistant professor of comparative biosciences at the University of Wisconsin, Madison, who previously worked in the Svendsen Laboratory and remains a close collaborator, recently found that stem cells derived from human bone marrow and engineered to produce GDNF protected nerve cells, improved motor function and increased lifespan when transplanted into muscle groups of a rat model of ALS.

"It seems clear that GDNF has potent neuroprotective effects on motor neuron function when the protein is delivered at the level of the muscle, regardless of the delivery method. We think GDNF will be able to help maintain these connections in patients and thereby keep the motor neuron network functional," Suzuki said.

Svendsen's team now plans to directly deliver GDNF into muscle cells with AAV5, a "viral vector" a virus stripped of its harmful genes and engineered to carry a beneficial gene into targeted cells. This will be supplied by uniQure, a biotechnology company that is collaborating with several research centers to conduct gene therapy clinical trials targeting other diseases.

In the new lab rat studies, AAV5 will be engineered to deliver GDNF into muscle tissue of the leg and the diaphragm, addressing two major aspects of ALS.

"The disease's effects typically start in one limb, beginning with weakness and leading to paralysis, before moving to other limbs and to muscles throughout the body. The most common cause of death is respiratory failure when the diaphragm muscles become incapacitated," said Svendsen, who has studied ALS for more than a decade and whose team will perform the leg muscle studies while Suzuki's group conducts the respiratory muscle experiments.

The Department of Defense grant will support all animal studies needed to take these experiments from the bench side to the bedside leading to the filing of an Investigational New Drug application with the Food and Drug Administration. The IND process is a regulatory step between preclinical study and human clinical trials. If approved, Cedars-Sinai's large ALS Program, led by Robert H. Baloh, MD, PhD, has a clinical trials group in place to move this research into the clinic.

"Muscle is much more readily accessible for treatment and biopsy than brain tissue or the spinal cord, which makes this strategy very appealing," Svendsen said. "Our previous findings provide strong evidence that the viral vector can transfer the GDNF protein into muscle, and we have shown that GDNF delivered to muscle may slow disease progression. We appreciate the Department of Defense's interest and funding, which will make it possible for us to further this exciting research."

Svendsen's research group in 2012 received a $17.8 million grant from the California Institute for Regenerative Medicine to develop stem cell treatments for patients with ALS based on injections of stem cells releasing GDNF into the spinal cord.


'/>"/>

Contact: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Marriage linked to lower heart risks in study of 3.5+ million adults
2. Scripps Florida scientist awarded $2.3 million to study dengue fever and related viruses
3. The Brain & Behavior Research Foundation awards $4 million in NARSAD Grants
4. Einstein helps establish $28 million consortium to find ebola treatment
5. Stroke in children will be focus of $3 million grant
6. UTMB receives $3.2 million to continue collaborative research on cancer in Texas
7. NCI recommends the Wistar Institute receive $14.9 million support grant renewal
8. Cancer treatment, artery repair are goals of $3 million in NIH grants
9. UC Irvine stem cell researchers awarded $1.54 million in state funding
10. UCSF receives $50 million gift
11. UCSF team wins $2.7 million grant for innovative project to reduce premature births
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
Breaking Medicine Technology: